{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06525298",
            "orgStudyIdInfo": {
                "id": "EIS-12656C01"
            },
            "organization": {
                "fullName": "Eisbach Bio GmbH",
                "class": "INDUSTRY"
            },
            "briefTitle": "EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors",
            "officialTitle": "A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "eis-as-single-agent-and-in-combination-in-patients-with-specified-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-17",
            "studyFirstSubmitQcDate": "2024-07-24",
            "studyFirstPostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eisbach Bio GmbH",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).",
            "detailedDescription": "The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and preliminary efficacy of EIS-12656 alone or in combination with a PARPi or T-DXd in patients with specified advanced or metastatic solid tumors with homologous recombination deficient (HRD) mutations.\n\nIn the Phase 1 dose escalation phase participants will receive ascending doses of EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe dose for the Phase 2 part.\n\nIn the Phase 2 dose expansion phase participants will either receive EIS-12656 monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination with a PARPi or T-DXd (Modules 2 and 3). The objective is to evaluate the safety and tolerability and anti-tumor activity of EIS-12656 alone or in combination."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Homologous Recombination Deficiency",
                "HRR Deficiency"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 144,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "EIS-12656 Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: EIS-12656"
                    ]
                },
                {
                    "label": "Dose Expansion Module 1 (EIS-12656 Monotherapy)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: EIS-12656"
                    ]
                },
                {
                    "label": "Dose Expansion Module 2 (EIS-12656 + Olaparib)",
                    "type": "EXPERIMENTAL",
                    "description": "EIS-12656 will be given in combination with Olaparib",
                    "interventionNames": [
                        "Drug: EIS-12656",
                        "Drug: Olaparib"
                    ]
                },
                {
                    "label": "Dose Expansion Module 3 (EIS-12656 + T-DXd)",
                    "type": "EXPERIMENTAL",
                    "description": "EIS-12656 will be given in combination with Trastuzumab deruxtecan",
                    "interventionNames": [
                        "Drug: EIS-12656",
                        "Drug: Trastuzumab deruxtecan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "EIS-12656",
                    "description": "EIS-12656 tablets given daily",
                    "armGroupLabels": [
                        "Dose Expansion Module 1 (EIS-12656 Monotherapy)",
                        "Dose Expansion Module 2 (EIS-12656 + Olaparib)",
                        "Dose Expansion Module 3 (EIS-12656 + T-DXd)",
                        "EIS-12656 Dose Escalation"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olaparib",
                    "description": "as per USPI/SmPC",
                    "armGroupLabels": [
                        "Dose Expansion Module 2 (EIS-12656 + Olaparib)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trastuzumab deruxtecan",
                    "description": "as per USPI/SmPC",
                    "armGroupLabels": [
                        "Dose Expansion Module 3 (EIS-12656 + T-DXd)"
                    ],
                    "otherNames": [
                        "Enhertu"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)",
                    "description": "Number and percentage of participants with adverse events, serious adverse events, adverse events of special interest including changes in safety lab parameters, physical examinations, vital signs, and electrocardiogram (ECG)",
                    "timeFrame": "From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)"
                },
                {
                    "measure": "Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)",
                    "description": "A DLT is defined as an EIS-12656 related adverse event during the first treatment cycle that meets the criteria outlined in the study protocol",
                    "timeFrame": "Within 21 days of first dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum plasma concentration of EIS-12656 (Cmax)",
                    "description": "The concentration of EIS-12656 in plasma will be determined (Cmax will be derived)",
                    "timeFrame": "At pre-defined intervals from pre-dose Day 1 to Day 29"
                },
                {
                    "measure": "Area under the curve (AUC0-24)",
                    "description": "The AUC0-24 reflects the actual body exposure to drug over the last 24h dosing interval",
                    "timeFrame": "At pre-defined intervals from pre-dose Day 1 to Day 29"
                },
                {
                    "measure": "Time to maximum concentration (Tmax)",
                    "description": "The concentration of EIS-12656 in plasma will be determined (Tmax will be derived)",
                    "timeFrame": "At pre-defined intervals from pre-dose Day 1 to Day 29"
                },
                {
                    "measure": "Overall Response Rate",
                    "description": "Overall response rate defined as percentage of participants with the best overall response of confirmed CR or confirmed PR according to RECIST v1.1",
                    "timeFrame": "From screening to disease progression (approximately 1 year)"
                },
                {
                    "measure": "Duration of Response",
                    "description": "Time from first response to progression or death, as defined by RECIST 1.1",
                    "timeFrame": "From screening to disease progression or death (approximately 1 year)"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "Time from first dose of EIS-12656 to progression or death, as defined by RECIST 1.1",
                    "timeFrame": "From screening to disease progression or death (approximately 1 year)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Recurrent locally advanced or metastatic solid tumors\n* Homologous recombination deficient mutations\n* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy\n* Measurable disease (RECIST 1.1 Criteria)\n* Adequate organ and bone marrow function\n* ECOG Performance Status 0 or 1\n* Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* History or evidence of any clinically relevant gastrointestinal disease\n* Radiation therapy within \u22642 weeks\n* Significant cardiovascular disease\n* Uncontrolled, active, symptomatic brain metastases",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Adrian Schomburg",
                    "role": "CONTACT",
                    "phone": "+49 17621046886",
                    "email": "adrian@eisbach.bio"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Timothy Yap",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy Yap",
                            "role": "CONTACT",
                            "phone": "713-563-1784",
                            "email": "TYap@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                },
                {
                    "id": "C000531550",
                    "term": "Olaparib"
                },
                {
                    "id": "C000614160",
                    "term": "Trastuzumab deruxtecan"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233003",
                    "name": "Olaparib",
                    "asFound": "Improvement",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233243",
                    "name": "Trastuzumab deruxtecan",
                    "asFound": "Tilt",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}